CPIN Faculty Members

We would like to welcome Dr. George Ibrahim, MD, PhD, FRCSC, FAANS, FACS (Associate Professor, Institute of Biomedical Engineering, Institute of Medical Sciences,  Department of Surgery, U of T; Pediatric Neurosurgeon, Abe Bresver Chair in Functional Neurosurgery, Hospital for Sick Children; Scientist, Neurosciences and Mental Health, SickKids Research Institute) as a new faculty member to the CPIN community.

His clinical and research interests include the surgical treatment of medically intractable epilepsy, spasticity and functional disorders in children. He plays a leading role comprehensive epilepsy, dorsal rhizotomy and deep brain stimulation programs at SickKids. His research lab is dedicated to the study of neural networks in children with epilepsy and functional disorders through a combination of connectomic, computational neuroscience and machine learning approaches. His work has been published in over 200 peer-reviewed journals and is funded by several organizations, including the Canadian Institutes of Health Research. Dr. Ibrahim received several awards and recognitions including being named as one of Canada's Top 40 under 40 in 2019.

We would like to welcome Dr. Ina Anreiter (Assistant Professor, Department of Biological Sciences, University of Toronto Scarborough; Departments of Cell & Systems Biology and Ecology & Evolutionary Biology, University of Toronto) as a new faculty member to the CPIN community.

Dr. Anreiter's research interests center around how animal behaviour is regulated throughout development and in response to experience. Her lab’s current research focuses on understanding the role of epigenetic and epitranscriptomic gene regulation in development, behavior, and health and disease. Dr. Anreiter completed a BSc in Biology and a MSc in Molecular Genetics and Biomedicine at the University of Lisbon. Having developed an interest in animal behaviour, she subsequently pursued her Doctorate under supervision of Dr. Marla Sokolowski at the University of Toronto, studying how epigenetic mechanisms regulate gene expression to affect individual differences in behaviour. After her PhD, Dr. Anreiter was awarded the prestigious Schmidt Science Fellowship, which allowed her to pivot into computer science for a year under supervision of Dr. Jared Simpson, a leading expert in Oxford Nanopore Sequencing tool development. Her work with Dr. Simpson focused on leveraging new computational methods to assess transcriptomic marks on mRNA. Before starting her current appointment at the University of Toronto, Dr. Anreiter worked with Dr. Thomas Clandinin at Stanford University School of Medicine as an inaugural Stanford Science Fellow, to study the role of epitranscriptomics mechanisms in brain development, brain function, and behaviour.

We would like to welcome Dr. Katharine Dunlop (Assistant Professor, Department of Psychiatry, University of Toronto; Staff Scientist, Centre for Depression and Suicide Studies, St. Michael’s Hospital) as a new faculty member to the CPIN community.

Dr. Dunlop completed her PhD in Neuroscience at the University of Toronto in 2018, followed by a 3-year postdoctoral fellowship at Weill Cornell Medicine in New York City. She was the first recipient of the CPIN Jonathan Dostrovsky Award in Neuroscience in 2016. Dr. Dunlop’s current research program integrates graduate and postgraduate training in: developing and applying novel antidepressant therapies such as non-invasive brain stimulation; developing computational models using functional neuroimaging; and understanding cognitive and behavioural heterogeneity in healthy and depressed people. Currently, she is interested in developing computational, multivariate neuroimaging and neurostimulation approaches in suicide research.

We would like to welcome Dr. Joshua D. Rosenblat (Assistant Professor, Clinician-Investigator, Department of Psychiatry, University of Toronto; Psychiatrist and Clinician-Researcher, Mood Disorders Psychopharmacology Unit (MDPU), Toronto Western Hospital; Medical Director, Canadian Rapid Treatment Centre of Excellence (CRCTE; Braxia Health); Chief Medical & Scientific Officer; Braxia Scientific; Co-Founder, 1907 Research) as a new faculty member to the CPIN community.

Dr. Rosenblat completed his Bachelors of Science at the University of Toronto. He then completed his medical degree at the Schulich School of Medicine at the University of Western Ontario (UWO). He returned to Toronto to complete his residency training in the Department of Psychiatry where he also served as the Chief Resident of the Clinician-Scientist Program (CSP). Throughout medical school and residency, he conducted clinical research on novel pharmacological interventions for mood disorders. He then completed his graduate training in the Department of Pharmacology & Toxicology, studying the effects of ketamine for depression.

Dr. Rosenblat’s clinical focus is on mood disorders, with specialized expertise in pharmacological treatments. He conducts clinical trials to identify and evaluate novel psychopharmacological interventions for mood disorders that may substantially improve patient outcomes. Specific research programs currently underway include clinical trials evaluating ketamine and psilocybin assisted therapy for bipolar and unipolar depression. He has authored and co-authored >150 journal articles and textbook chapters in prestigious journals, such as the New England Journal of Medicine, JAMA Psychiatry, the American Journal of Psychiatry and the Journal of Clinical Psychiatry. He has received numerous local, national and international grants and awards for his research in mood disorders.

We would like to welcome Dr. Brad Wouters (Professor,  Departments of Medical Biophysics and Radiation Oncology, University of Toronto; Executive Vice President Science & Research, UHN; Senior Scientist, Princess Margaret Cancer Centre) as a new faculty member to the CPIN community.

Dr. Brad Wouters was also Princess Margaret Cancer Centre's Interim Research Director (2014–2016). His research program examines the molecular mechanisms underlying how hypoxia and the tumour microenvironment affect cancer biology and therapeutic outcome. 

As EVP of Science and Research, Dr. Wouters is focused on creating an environment that incentivizes, facilitates and rewards excellence in research across all elements of UHN. To this end, he led the development of UHN’s 2019–23 Strategic Research Plan, which incorporates team science and collaborative strategies to achieve UHN’s goals for research impact and organizational excellence. One of the signature priorities of this plan is to be a leader in embedding principles of equity, diversity and inclusion into all aspects of the institution’s research enterprise—such as the selection of prestigious chair positions, engaging youth from underrepresented backgrounds and providing education and training for leaders on global best practices.